Posts Tagged ‘Oncology’

Page 1 of 41234

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today launched its new TomoTherapy® H™ Series, featuring the TomoHDA™ System, with faster planning, faster delivery and increased quality. The TomoHDA System was unveiled at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston. Key features of the TomoHDA System include:

Accuray’s new TomoEDGE™ dynamic jaws technology provides users with added flexibility in treatment delivery by sharpening dose fall off and accuracy. In many cases the use of TomoEDGE for head and neck tumors and prostate cancer treatments has resulted in the reduction of beam-on time by half. With the TomoHDA™ System this new technology is standard and can be applied to both TomoHelical™ and TomoDirect™ treatment modes for 3DCRT and IMRT deliveries.

The high-performance VoLO™ Technology – an enhancement to the TomoTherapy® treatment planning system – leverages the new dose calculation algorithm and advanced graphics processing technology to increase clinical efficiency, throughput and flexibility in developing both simple and the most complex radiation therapy plans.

“We are committed to our TomoTherapy customers and continue to innovate to provide the most advanced treatments in radiation oncology with the goal of improving patient care,” said Joshua H. Levine, president and chief executive officer of Accuray. “The new TomoTherapy H™ Series offers treatment solutions for the entire spectrum of radiation therapy. It will enable unprecedented speed and efficiency ensuring the highest quality of care from the routine to the most complex cases.”

The TomoHDA System is a fully-integrated 3D image-guided, full spectrum radiation therapy system and builds upon the proven TomoTherapy Hi-Art® and TomoHD™ technologies. The TomoHDA System offers multiple new benefits including performance enhancements, unrivaled dose distributions and faster treatments.

The TomoHDA System is part of the new TomoTherapy H Series. Included in this series of products, is the new TomoH™ System, the gold standard for image-guided IMRT (intensity-modulated radiation therapy) treatment, providing streamlined 3D CT daily image guidance and ultrafast MLC (multileaf collimator) modulation, enabling the delivery of the dose to achieve excellent target homogeneity while sparing surrounding healthy tissue. Also included in the series is the TomoHD™ System – including TomoDirect – a full spectrum solution that provides high quality treatments to every patient for any clinical indication requiring radiotherapy.

The new TomoEDGE™ dynamic jaws are capable of sharpening the dose and allow customers to treat more patients with the TomoTherapy System. The jaws are optimized to sweep across the target, minimizing dose to healthy tissue and critical structures adjacent to the target and opening to the desired maximum size to reduce treatment time. The result is a balanced treatment delivery that is as unique as each patient.

Using the high-performance VoLO Technology, the TomoHDA™ system allows ultra fast creation of highly conformal treatment plans with the flexibility to design a personalized treatment plan specific to the individual needs of each patient. For example, the application of VoLO technology on breast cancer treatment plans has been shown to reduce dose calculation and treatment planning optimization time to as few as three minutes. TomoHDA also includes a fan-beam computed tomography (CT) system capable of producing images 50 percent faster, facilitating improved patient re-positioning time and therefore less overall time for the patient to be on the treatment couch.

“Having been involved in the creation of and research collaboration for the new TomoEDGE, we have seen firsthand that this is one of the most versatile radiation therapy treatment options available,” said PD Dr. Florian Sterzing, M.D., Consultant Radiation Oncologist at University Clinic of Heidelberg. “The new functionality enables improved quality of radiotherapy application and allows us to treat even more cancer patients.”

The TomoHDA System also includes Citrix®-based remote planning with web-based review capabilities, providing the ultimate flexibility for clinicians to develop and approve treatment plans from virtual workstations.

“TomoTherapy’s ability to treat the full range of disease sites, including even the most complex tumors, makes it an invaluable resource for cancer patients,” said Wade Gebara, M.D. Chief of Radiation Oncology at Berkshire Medical Center, Pittsfield, Mass. “With increased speed and reliability, the new TomoTherapy System will provide the opportunity for more patients to benefit from this personalized technology.”

Also on display in Accuray’s ASTRO booth (#7101) is the CyberKnife M6 FIM Sytem – part of the CyberKnife® M6™ Series – which is pending FDA 510(k) clearance and not yet available for commercial distribution in the United States. The new CyberKnife M6 FIM and FM Systems feature the InCise™ Multileaf Collimator, which combines the benefits of beam shaping with the flexibility of non-isocentric, non-coplanar delivery. The new InCise Multileaf Collimator (MLC) was designed specifically for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, giving the system the capability to extend its radiosurgical precision into a broader field of applications. The system is intended to treat large and irregular tumors more efficiently with excellent dose gradients, to expand the number of patients eligible for treatment.

Researchers at Fox Chase Cancer Center in Philadelphia – who compared treatment plans created with a theoretical MLC on the CyberKnife System to those created originally with the CyberKnife Iris™ Collimator and conventional Intensity-Modulated Radiation Therapy (IMRT) plans – found that an MLC mounted on a robotic arm could potentially offer numerous clinical benefits, including faster treatment delivery, better target coverage and a sharper dose fall off could be achieved than a typical gantry- based IMRT plan or previous CyberKnife treatments. The Fox Chase researchers demonstrated the potential to create treatment plans that would spare critical structures around tumors better with a robotically mounted MLC, providing the ability to treat tumors using a higher dose without increasing the normal tissue toxicity.

Dates, times and locations of ASTRO clinical presentations featuring the CyberKnife and TomoTherapy Systems are available here.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expansion of the Company’s global presence, quality of treatments, accuracy, dose delivery, clinical efficiency, continual innovation, pending regulatory clearance, treatment times, dose sculpting, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

The TomoTherapy® System, the premier solution for the entire spectrum of radiation therapy — that delivers dose only where you need it — now with outstanding speed, performance and simplicity — allowing you the freedom to choose the very best treatment for each of your patients, with confidence and without compromise.

Created to make personalized treatments an option for radiation therapy, the TomoTherapy H Series offers interactive planning and efficient delivery of highly sculpted doses for personalized and consistent treatments. Seamless daily CT image guidance provides precise patient positioning, margin reduction and adaptive planning and enables pinpoint dose accuracy for every radiation therapy patient.

Accuray launched its new TomoTherapy H Series line of radiation oncology devices, headlined by the 3D image guided TomoHDA System with TomoEDGE technology. TomoEDGE optimizes radiation delivery by sharpening the affected edge between the target tumor and healthy tissue.

Accuray TomoTherapy H Series table Accurays New TomoTherapy H Series of Radiation Oncology Devices (VIDEO)

The company’s VoLO technology takes into account the new radiation dose delivery pattern into its calculations when doing graphic analysis in preparing treatment plans.

The three devices in the TomoTherapy H Series:

The TomoHDA™ System – the ultimate flexibility in treatment delivery with unrivaled dose conformality, faster patient treatments, and faster concurrent treatment planning. It grants everypatient access to high quality treatment

TomoEDGE™ spares more normal tissue while enabling increased throughput —with unprecedented quality

High performance VoLO™ planning provides flexibility, speed, efficiency and interactivity for concurrent treatment planning

Expand your practice by efficiently treating patients that are difficult to treat with conventional radiation therapy equipment

The TomoHD™ System- the full spectrum solution for any Radiation Oncology center, providing high quality treatments to every patient for any clinical indication requiring radiotherapy

TomoHelical™ and TomoDirect™ modalities to enable delivery of individualized treatments for both routine and complex indications

VoLO planning provides the ultimate in flexibility, speed and efficiency with real time interactive planning

The clinical solution when accuracy, flexibility and efficiency cannot be compromised

The TomoH™ System- the gold standard for image guided IMRT treatment delivery maximizes both conformality and target dose uniformity

CTrue™ image guidance provides daily 3D CT target localization and enables margin reduction while sparing healthy tissue

Ultra-fast binary MLC enables unprecedented intensity modulation

Excellent target homogeneity while sparing more normal healthy tissue

Source : http://www.accuray.com/media/press-releases/accuray-launches-new-tomotherapy%C2%AE-h%E2%84%A2-series-featuring-tomoedge%E2%84%A2

Full story

EMUC discusses current and future prospects in imaging for prostate cancer

EMUC discusses current and future prospects in imaging for prostate cancer

At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.

“The future of imaging for prostate cancer has already begun,” said radiologist G. Villeirs (BE) in his overview lecture on current and future prospects in imaging for prostate cancer. Villeirs enumerated several technologies that can provide or improve current imaging techniques such as T2 Weighted MRI (Magnetic Resonance Imaging), Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced MRI, Magnetic Resonance (MR) spectroscopy and Multiparametric MRI.

Many of these techniques have been undergoing research tests and refinements, according to Villeirs as he added that it would be a matter of time when the optimal use of these techniques will provide uro-oncological experts the benefits of more accurate, insightful diagnoses.

“In dynamic contrast-enhanced MRI, its most important use is in detection and localisation (of prostate tumours), with an accuracy of up to 90%,” he said.

M. Rubin (USA) spoke on the research developments in biomarkers and noted that diseases like castration resistant prostate cancer (CRPC), for instance, remains a challenge to researchers due to its heterogenous nature. He mentioned that the next generation of PCa biomarkers are urine-based assays (which detects early aggressive PCa), and tissue/CTC-based assays which are employed for prediction and precision medicine.

Urine-based assays include PCA3 (already FDA-approved), TMPRSS2-ERG (in development), other fusions (in development) and SPOP/CHD1 (early discovery), while tissue-based assays include androgen receptor gene (AR), BRCA2 and AURKA. Rubin said that TMPRSS2-ERG which has a specificity of 97% and sensitivity of 96% is commercially available for clinical use in the US and Europe.

The unmet biomarker needs for PCa, according to Rubin, should address the following aims: to distinguish BPH from prostate cancer, to detect the aggressive forms from the indolent cases and to identify the metastatic cancer predictors.

Meanwhile, urologist A. Briganti (IT) gave a comprehensive update on the future of surgery for prostate cancer and his expectations in the coming years. “We need to perform the correct surgery – in the right patient – to decrease the need for secondary therapies,” said Briganti, adding that identifying the right patient for the correct surgery is “…key in optimizing the future of surgery.”

He explained that correctly prescribed surgery will have the higher chance of cure only “…if combined with adjuvant therapy and delivered only to those patients who really deserve it.” He also expects that minimally invasive approaches will change the toxicity profile of more extensive surgical approaches.

“But data are still lacking,” Briganti noted.

M. Van Vulpen (NL) presented the radiation oncologist viewpoint regarding external beam radiotherapy and brachytherapy, while J. De Bono (UK) took up the topic of future medical therapies in prostate cancer.

Van Vulpen also expressed confidence that radiotherapy will remain in the forefront of new developments as he noted several breakthrough developments such as CT-linac (linear accelerator) which is used when prostate movements are problematic for intensity-modulated radiotherapy. He also mentioned computerised tumour detection which can localise tumour and show its aggressiveness.

De Bono gave a thorough overview on medical therapies, stressing that cancer experts should aim to decrease over diagnosis of benign PCa and the over treatment of ‘benign’ disease. De Bono noted that to improve therapeutic options doctors need to cure more high-risk/intermediate disease and improve the outcome from metastatic PCa.

He explained that three elements are important in improving treatment outcomes, namely an improved biological understanding of PCa, developing deliverable biomarkers that can be used for precision medicine, and by developing new drugs through hypotheses testing and are biomarker-driven.

Source : http://www.news-medical.net/news/20121119/EMUC-discusses-current-and-future-prospects-in-imaging-for-prostate-cancer.aspx

Full story

Biomolecular imaging: an interview with Professor Roger Reddel

Biomolecular imaging: an interview with Professor Roger Reddel

Please could you give a brief introduction to the Children’s Medical Research Institute’s (CMRI) discovery program?

The reason Children’s Medical Research Institute (CMRI) exists is to find ways to treat or prevent childhood disease. Our research programs are focussed on the areas of cancer cell growth, nerve cell signalling, embryology and gene therapy. These four programs have a shared aim of translating novel findings into new treatments for the benefit of families everywhere.

We are developing new medicines to treat cancer, epilepsy, kidney disease and infectious disease. Our Gene Therapy Unit, a collaboration with the neighbouring Children’s Hospital at Westmead, conducted the first ever gene therapy clinical trial in Australia, and they are continuing to make improvements in gene therapy technology. They now have two gene therapy clinical trials ongoing, one to help children with inherited liver disease and one to improve chemotherapy treatment for brain tumours.

We are currently working towards a building expansion that will increase our number of researchers and our research output, as well as provide much needed space for the national research facilities that we operate for the benefit of researchers throughout Australia: CellBank Australia and The ACRF Centre for Kinomics.

You have recently received a grant from the Ramaciotti Foundations to purchase a Typhoon FLA9500 Biomolecular Imager. What can this biomolecular imager be used to visualise?

The imager can help visualise DNA, RNA and protein, the latter being crucial to proteomics work.

How will this piece of equipment aid the expansion of CMRI’s discovery program?

The imager, which Ramaciotti Foundations have kindly helped support, is used by all of our research groups, and is especially useful for studying telomerase, one of the key factors in 85% of all cancers.

This new imager is essential, however, to increase the throughput of our mass spectrometry work.

CMRI houses a Biomedical Proteomics facility that collaborates with researchers across New South Wales, and it also operates The ACRF Centre for Kinomics, a unique national resource that is available to researchers across Australia to aid the development of therapeutic drugs for a range of diseases including epilepsy, asthma, heart disease, infectious diseases and cancer.

All of this work requires expensive mass spectrometry equipment and the know-how to run it, but processing the samples prior to mass spectrometry requires a biomolecular imager. This new machine will play a vital role in allowing us to take full advantage of our proteomics facilities.

Please could explain what telomerase is? Why is it one of the key factors in 85% of cancers?

The DNA inside every cell of our bodies is packaged into chromosomes. The ends of chromosomes are called telomeres and they have a specialised structure that helps to protect chromosomes from being damaged. But each time a cell reproduces itself, its telomeres wear down a little bit. This acts as a counting mechanism determining the maximum number of times a cell can divide and may be one of the causes of aging.

Cancer cells, however, are able to ignore this countdown clock and keep growing indefinitely. The way they do this is by adding back new telomere DNA to the ends of chromosomes to prevent them wearing down. 85% of all cancers use an enzyme called telomerase to add back this telomere DNA. If we can find a way to block the action of telomerase in cancer cells, we can stop them from growing.

What further study is needed into telomerase and how exactly will this new imager help to achieve this?

CMRI’S Cell Biology Unit is studying the telomerase protein in great detail to understand how every part of it works. One of the approaches they take is to remove the function of small parts of the enzyme to see what effect this has, which allows them to build up a picture of how all the parts of the enzyme work together.

This approach requires them to measure how well telomerase works after they have made these alterations. These measurements require a Typhoon imager in order to visualise the DNA telomerase is adding on to telomeres. The Cell Biology Unit also needs the Typhoon to help study the telomerase protein itself. They expect that their work will reveal the best target areas within telomerase to aim for when designing new anti-cancer drugs.

Why is it necessary to use a biomolecular imager to process samples prior to mass spectrometry?

Proteins for mass spectrometry study usually come from complex mixtures and first need to be separated from one another by methods such as a polyacrylamide gel. This is a jelly-like material to which an electric field is applied to separate proteins from one another based on their size and electric charge. Then, in order to visualise the proteins, the Typhoon imager is needed.

Next, they are prepared for mass spectrometry analysis. Mass spectrometry analysis requires extensive preparation of samples ahead of time and purification of those samples using either gels (requiring a Typhoon) or HPLC (another instrument that helps separate proteins). The method used depends on the type of analysis that the researchers require.

How does the new biomolecular imager differ from current instruments owned by the CMRI?

It detects a greater range of wavelengths, is more reliable and has higher throughput capabilities.

Why does the new imager have higher throughput capabilities?

The instrument we’ve chosen can hold more polyacrylamide gels at once than other imagers that are currently available —thus increasing throughput.

What research benefits do you hope will come from this Biomolecular Imager?

We hope the new imager will seamlessly integrate with our current research programs and also provide the capacity for expansion as CMRI grows over the next few years.

It will have a role to play in diverse areas of research ranging from a detailed understanding of the role of the telomerase enzyme in cancer, to helping to identify other proteins involved in cancer, neurological conditions including epilepsy, and a variety of other diseases.

Would you like to make any further comments?

As ever, we are extremely grateful for Ramaciotti Foundations’ support of our work. The Ramaciotti Foundations are a vital source of funding for the specialised equipment that our research depends on.

Where can readers find more information?

www.cmri.org.au

About Professor Roger Reddel

Roger Reddel BIG IMAGERoger Reddel is Director of Children’s Medical Research Institute (CMRI), and the Sir Lorimer Dods Professor, Sydney Medical School, University of Sydney. He also heads CMRI’s Cancer Research Unit, and directs CellBank™ Australia.

He obtained his medical degrees from the University of Sydney, trained in medical oncology at Royal Prince Alfred Hospital, and is a Fellow of the Royal Australasian College of Physicians.

Roger completed a PhD in cancer cell biology at the Ludwig Institute for Cancer Research in the University of Sydney’s Department of Cancer Medicine, and received an NHMRC CJ Martin Fellowship and a Fulbright Fellowship to undertake postdoctoral research at the National Cancer Institute, Bethesda, Maryland, USA.

He returned to Sydney to establish a laboratory at CMRI, attracted by the Institute’s culture of fostering high quality basic research, and with the support of Cancer Council NSW’s Bicentennial Fellowship.

He has continued to receive major support from the Cancer Council, including being awarded the Carcinogenesis Fellowship for ten years, and Program Grants for ten years. His team is also supported by Cancer Institute NSW, the Judith Hyam Memorial Trust Fund for Cancer Research, Rotary Club of Sydney, and the National Health and Medical Research Council of Australia.

Professor Reddel was awarded the Ramaciotti Medal for Excellence in Biomedical Research in 2007, was elected as a Fellow of the Australian Academy of Science in 2010, and in 2011 received the NSW Premier’s Award for Outstanding Cancer Researcher of the Year.

Professor Reddel is a director of Cure Cancer Australia Foundation. He serves on editorial boards of a number of international cancer research journals, and on national and international scientific advisory panels.

Source : http://www.news-medical.net/news/20121119/Biomolecular-imaging-an-interview-with-Professor-Roger-Reddel.aspx

Full story

FDA approves Cook’s Zilver PTX drug-eluting peripheral stent

FDA approves Cook’s Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. (“Angiotech”) announced that its partner Cook Medical, Inc. (“Cook”) received approval on November 15, 2012 from the U.S. Food and Drug Administration (“FDA”) to market and sell the proprietary Zilver® PTX® drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. Zilver PTX is the first drug-eluting stent indicated for use in peripheral artery disease approved by the FDA.

“We wish to offer our congratulations to Cook Medical on this important milestone in the development and commercialization of Zilver PTX,” said Thomas Bailey, President and CEO of Angiotech. “The use of paclitaxel to treat restenosis is Angiotech’s founding technology platform, and we are excited to see this technology further developed and commercialized by Cook in a truly novel product for the treatment of peripheral vascular disease.”

Cook’s Zilver PTX peripheral stent incorporates Angiotech’s proprietary paclitaxel technology, which was first commercialized by Angiotech’s partner Boston Scientific Corporation (“BSC”) in the TAXUS® stent platform for the treatment of coronary artery disease. Paclitaxel eluting stents have been shown in multiple clinical studies, in both coronary and peripheral vascular disease, to reduce rates of repeat blockages, or restenosis, following initial implantation of a stent in diseased vessels.

Data from Cook’s pivotal clinical trial indicate that eight out of 10 patients treated with Zilver PTX still had open arteries (primary patency) after one year, as compared to only three out of 10 patients treated with balloon angioplasty alone. In addition, patients who received a bare metal stent required more than twice as many reintervention procedures to reopen the treated vessel as compared to patients who received Zilver PTX.

Cook and BSC originally licensed Angiotech’s proprietary paclitaxel technology in 1997. Angiotech receives royalties from Cook derived from Cook’s sales of Zilver PTX.

Source : http://www.news-medical.net/news/20121116/FDA-approves-Cooks-Zilver-PTX-drug-eluting-peripheral-stent.aspx

Full story

Port-a-Cath Gets CT Marks

Port-a-Cath Gets CT Marks

Port-a-Cath Gets CT Marks

St. Paul, MN, January 5, 2011 — Smiths Medical, a leading global medical devices manufacturer, announced today that they have launched new implantable ports with CT identifiers for easy viewing using X-rays or CT scout scans. The implantable ports facilitate quick acknowledgement that the ports can be used for power injection of contrast media.

The PORT-A-CATH® and P.A.S. PORT® POWER P.A.C. implantable access systems now include an easy-to-see CT identifier on the top of each port. Unlike other ports where the C and T letters are located on the bottom of the portal, and often have to be read backwards under scout scans, PORT-A-CATH® and P.A.S. PORT® POWER P.A.C. systems contain a radiopaque CT identifier that is embedded into the top of the port septum for easy, normal viewing.

Implantable access systems provide a route of delivery for patients requiring long-term medication therapy such as chemotherapy. The portal is implanted under the skin and connected to a catheter that is threaded into a vein. Power injecting may be performed when a patient requires a Contrast Enhanced Computed Tomography (CECT) scan for diagnostic purposes. The power injection procedure requires use of an implantable port, such as the PORT-A-CATH®, PORT-A-CATH® II or P.A.S. PORT® T2 POWER P.A.C. implantable access systems, that can withstand higher pressure and faster flow rates than standard medication infusions.

“Smiths Medical has millions of PORT-A-CATH® and P.A.S. PORT® systems implanted and in use today,” said Andrew Rose, Vice President Global Product Management, Safety Solutions. “Our port systems are known for being lightweight, easy to implant, easy to maintain during therapy, and easy to remove when no longer needed. The addition of a durable, easy-to-read CT identifier creates a system flexible for a variety of therapies. This system also reduces unnecessary needle sticks for patients since the port can be used for any of the patient’s IV access requirements, including power and non-power injection therapies.”

The new implantable ports are not yet available in all countries. Customers are advised to check with their local Smiths Medical representative for product availability.

Smiths Medical www.smiths-medical.comis a leading supplier of specialist medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. It is part of Smiths Group www.smiths.com, a global leader in applying advanced technologies for markets in threat and contraband detection, energy, medical devices, communications and engineered components. Smiths Group employs around 22,000 people in more than 50 countries.

Ports or portacaths are widely used in hematology and oncology patients for easy vascular access. However, not all of them can withstand power injection of contrast media and asking patients which port they have can be an unreliable method at times. That is why Smiths Medical has launched new versions of its implantable ports with radio-opaque identifiers which can be seen on X-ray and CT scout scans. The letters C and T are embedded into the top of the port, which, the company proudly announces, prevents them from being read backwards like might happen with other manufacturers’ products. Indeed that always confused us completely! Nevertheless, this is a nice little tweak to a useful product.

Source : http://www.smiths-medical.com/plugins/news/2011/jan/smiths-medical-launches-implantable.html

Full story

AngioDynamics’ NeverTouch Direct Procedure Kit for Varicose Veins

AngioDynamics’ NeverTouch Direct Procedure Kit for Varicose Veins

AngioDynamics’ NeverTouch Direct Procedure Kit for Varicose Veins

AngioDynamics Receives FDA Clearance for NeverTouch Direct™ Procedure Kit to be Used With the VenaCure EVLT® System

NeverTouch Direct Kit Allows Physicians to Treat Varicose Veins With Fewer Procedure Steps

ALBANY, N.Y., Feb. 14, 2012 (GLOBE NEWSWIRE) — AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. Food and Drug Administration has granted 510(k) clearance for its NeverTouch Direct™ Procedure Kit for use with the Company’s VenaCure EVLT® Laser Vein Ablation System. The NeverTouch Direct kit offers physicians the ability to treat varicose veins with fewer procedure steps — by eliminating the need for a long guide wire or guiding sheath — while continuing to deliver to patients less pain and bruising compared to bare-tip fibers.

“NeverTouch Direct and the sheathless fiber option further expands the physician’s ability to tailor treatment to each individual patient, and avoid one-size-fits-all approaches that limit the physician’s ability to exercise their clinical judgment,” said Alan Panzer, Senior Vice President and General Manager for AngioDynamics. “Taken together with the advantages delivered by our new VenaCure® 1470 laser, and the new NeverTouch® 90cm fiber, AngioDynamics remains the clear choice for clinicians who demand tools that take advantage of their full range of skill and experience.”

The NeverTouch Direct kit, expected to launch in summer 2012, is indicated for endovascular coagulation of the great saphenous vein in patients with superficial vein reflux, for the treatment of varicose veins and varicosities associated with superficial reflux of the great saphenous vein, and for the treatment of incompetence and reflux of superficial veins of the lower extremity.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011, and AngioDynamics’ Form 10-Q for the quarterly period ended November 30, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics recently received FDA 510(k) clearance for its NeverTouch Direct Procedure Kit that’s used with the VenaCure EVLT Laser Vein Ablation System for treatment of varicose veins.

The new kit simplifies the procedure, taking out the need to use a long guide wire or guiding sheath to deliver laser energy. The product is scheduled for launch this Summer.

From the announcement:

“NeverTouch Direct and the sheathless fiber option further expands the physician’s ability to tailor treatment to each individual patient, and avoid one-size-fits-all approaches that limit the physician’s ability to exercise their clinical judgment,” said Alan Panzer, Senior Vice President and General Manager for AngioDynamics. “Taken together with the advantages delivered by our new VenaCure® 1470 laser, and the new NeverTouch® 90cm fiber, AngioDynamics remains the clear choice for clinicians who demand tools that take advantage of their full range of skill and experience.”

The NeverTouch Direct kit, expected to launch in summer 2012, is indicated for endovascular coagulation of the great saphenous vein in patients with superficial vein reflux, for the treatment of varicose veins and varicosities associated with superficial reflux of the great saphenous vein, and for the treatment of incompetence and reflux of superficial veins of the lower extremity.

Source : http://investors.angiodynamics.com/releasedetail.cfm?ReleaseID=648361

Full story

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

SUNNYVALE, Calif. and ASTRO 2012 (Boston), October 28, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today launched its new TomoTherapy® H™ Series, featuring the TomoHDA™ System, with faster planning, faster delivery and increased quality. The TomoHDA System was unveiled at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston. Key features of the TomoHDA System include:

Accuray’s new TomoEDGE™ dynamic jaws technology provides users with added flexibility in treatment delivery by sharpening dose fall off and accuracy. In many cases the use of TomoEDGE for head and neck tumors and prostate cancer treatments has resulted in the reduction of beam-on time by half. With the TomoHDA™ System this new technology is standard and can be applied to both TomoHelical™ and TomoDirect™ treatment modes for 3DCRT and IMRT deliveries.

The high-performance VoLO™ Technology – an enhancement to the TomoTherapy® treatment planning system – leverages the new dose calculation algorithm and advanced graphics processing technology to increase clinical efficiency, throughput and flexibility in developing both simple and the most complex radiation therapy plans.

“We are committed to our TomoTherapy customers and continue to innovate to provide the most advanced treatments in radiation oncology with the goal of improving patient care,” said Joshua H. Levine, president and chief executive officer of Accuray. “The new TomoTherapy H™ Series offers treatment solutions for the entire spectrum of radiation therapy. It will enable unprecedented speed and efficiency ensuring the highest quality of care from the routine to the most complex cases.”

The TomoHDA System is a fully-integrated 3D image-guided, full spectrum radiation therapy system and builds upon the proven TomoTherapy Hi-Art® and TomoHD™ technologies. The TomoHDA System offers multiple new benefits including performance enhancements, unrivaled dose distributions and faster treatments.

The TomoHDA System is part of the new TomoTherapy H Series. Included in this series of products, is the new TomoH™ System, the gold standard for image-guided IMRT (intensity-modulated radiation therapy) treatment, providing streamlined 3D CT daily image guidance and ultrafast MLC (multileaf collimator) modulation, enabling the delivery of the dose to achieve excellent target homogeneity while sparing surrounding healthy tissue. Also included in the series is the TomoHD™ System – including TomoDirect – a full spectrum solution that provides high quality treatments to every patient for any clinical indication requiring radiotherapy.

The new TomoEDGE™ dynamic jaws are capable of sharpening the dose and allow customers to treat more patients with the TomoTherapy System. The jaws are optimized to sweep across the target, minimizing dose to healthy tissue and critical structures adjacent to the target and opening to the desired maximum size to reduce treatment time. The result is a balanced treatment delivery that is as unique as each patient.

Using the high-performance VoLO Technology, the TomoHDA™ system allows ultra fast creation of highly conformal treatment plans with the flexibility to design a personalized treatment plan specific to the individual needs of each patient. For example, the application of VoLO technology on breast cancer treatment plans has been shown to reduce dose calculation and treatment planning optimization time to as few as three minutes. TomoHDA also includes a fan-beam computed tomography (CT) system capable of producing images 50 percent faster, facilitating improved patient re-positioning time and therefore less overall time for the patient to be on the treatment couch.

“Having been involved in the creation of and research collaboration for the new TomoEDGE, we have seen firsthand that this is one of the most versatile radiation therapy treatment options available,” said PD Dr. Florian Sterzing, M.D., Consultant Radiation Oncologist at University Clinic of Heidelberg. “The new functionality enables improved quality of radiotherapy application and allows us to treat even more cancer patients.”

The TomoHDA System also includes Citrix®-based remote planning with web-based review capabilities, providing the ultimate flexibility for clinicians to develop and approve treatment plans from virtual workstations.

“TomoTherapy’s ability to treat the full range of disease sites, including even the most complex tumors, makes it an invaluable resource for cancer patients,” said Wade Gebara, M.D. Chief of Radiation Oncology at Berkshire Medical Center, Pittsfield, Mass. “With increased speed and reliability, the new TomoTherapy System will provide the opportunity for more patients to benefit from this personalized technology.”

Also on display in Accuray’s ASTRO booth (#7101) is the CyberKnife M6 FIM Sytem – part of the CyberKnife® M6™ Series – which is pending FDA 510(k) clearance and not yet available for commercial distribution in the United States. The new CyberKnife M6 FIM and FM Systems feature the InCise™ Multileaf Collimator, which combines the benefits of beam shaping with the flexibility of non-isocentric, non-coplanar delivery. The new InCise Multileaf Collimator (MLC) was designed specifically for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, giving the system the capability to extend its radiosurgical precision into a broader field of applications. The system is intended to treat large and irregular tumors more efficiently with excellent dose gradients, to expand the number of patients eligible for treatment.

Researchers at Fox Chase Cancer Center in Philadelphia – who compared treatment plans created with a theoretical MLC on the CyberKnife System to those created originally with the CyberKnife Iris™ Collimator and conventional Intensity-Modulated Radiation Therapy (IMRT) plans – found that an MLC mounted on a robotic arm could potentially offer numerous clinical benefits, including faster treatment delivery, better target coverage and a sharper dose fall off could be achieved than a typical gantry- based IMRT plan or previous CyberKnife treatments. The Fox Chase researchers demonstrated the potential to create treatment plans that would spare critical structures around tumors better with a robotically mounted MLC, providing the ability to treat tumors using a higher dose without increasing the normal tissue toxicity.

Dates, times and locations of ASTRO clinical presentations featuring the CyberKnife and TomoTherapy Systems are available here.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expansion of the Company’s global presence, quality of treatments, accuracy, dose delivery, clinical efficiency, continual innovation, pending regulatory clearance, treatment times, dose sculpting, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

The TomoTherapy® System, the premier solution for the entire spectrum of radiation therapy — that delivers dose only where you need it — now with outstanding speed, performance and simplicity — allowing you the freedom to choose the very best treatment for each of your patients, with confidence and without compromise.

Created to make personalized treatments an option for radiation therapy, the TomoTherapy H Series offers interactive planning and efficient delivery of highly sculpted doses for personalized and consistent treatments. Seamless daily CT image guidance provides precise patient positioning, margin reduction and adaptive planning and enables pinpoint dose accuracy for every radiation therapy patient.

Clinical Excellence

Treats a full spectrum of radiotherapy patients without compromise

Enables planning and delivery of highly sculpted dose distributions

Patient Focus

Facilitates seamless daily CT image guidance for precise patient positioning, margin reduction and adaptive planning

Provides personalized and consistent treatments for every patient

Spares more normal tissue, helping to reduce side effects

Economic Impact

Schedule your radiation therapy patients in conventional time slots

Fast and flexible treatment planning for each individual patient

Automated quality assurance

The TomoTherapy H Series

The TomoHDA™ System – the ultimate flexibility in treatment delivery with unrivaled dose conformality, faster patient treatments, and faster concurrent treatment planning. It grants every patient access to high quality treatment

TomoEDGE™ spares more normal tissue while enabling increased throughput —with unprecedented quality

High performance VoLO™ planning provides flexibility, speed, efficiency and interactivity for concurrent treatment planning

Expand your practice by efficiently treating patients that are difficult to treat with conventional radiation therapy equipment

The TomoHD™ System – the full spectrum solution for any Radiation Oncology center, providing high quality treatments to every patient for any clinical indication requiring radiotherapy

TomoHelical™ and TomoDirect™ modalities to enable delivery of individualized treatments for both routine and complex indications

VoLO planning provides the ultimate in flexibility, speed and efficiency with real time interactive planning

The clinical solution when accuracy, flexibility and efficiency cannot be compromised

The TomoH™ System – the gold standard for image guided IMRT treatment delivery maximizes both conformality and target dose uniformity

CTrue™ image guidance provides daily 3D CT target localization and enables margin reduction while sparing healthy tissue

Ultra-fast binary MLC enables unprecedented intensity modulation

Excellent target homogeneity while sparing more normal healthy tissue

Accuray launched its new TomoTherapy H Series line of radiation oncology devices, headlined by the 3D image guided TomoHDA System with TomoEDGE technology. TomoEDGE optimizes radiation delivery by sharpening the affected edge between the target tumor and healthy tissue.

Accuray TomoTherapy H Series table Accurays New TomoTherapy H Series of Radiation Oncology Devices (VIDEO)

The company’s VoLO technology takes into account the new radiation dose delivery pattern into its calculations when doing graphic analysis in preparing treatment plans.

The three devices in the TomoTherapy H Series:

The TomoHDA™ System – the ultimate flexibility in treatment delivery with unrivaled dose conformality, faster patient treatments, and faster concurrent treatment planning. It grants everypatient access to high quality treatment

TomoEDGE™ spares more normal tissue while enabling increased throughput —with unprecedented quality

High performance VoLO™ planning provides flexibility, speed, efficiency and interactivity for concurrent treatment planning

Expand your practice by efficiently treating patients that are difficult to treat with conventional radiation therapy equipment

The TomoHD™ System- the full spectrum solution for any Radiation Oncology center, providing high quality treatments to every patient for any clinical indication requiring radiotherapy

TomoHelical™ and TomoDirect™ modalities to enable delivery of individualized treatments for both routine and complex indications

VoLO planning provides the ultimate in flexibility, speed and efficiency with real time interactive planning

The clinical solution when accuracy, flexibility and efficiency cannot be compromised

The TomoH™ System- the gold standard for image guided IMRT treatment delivery maximizes both conformality and target dose uniformity

CTrue™ image guidance provides daily 3D CT target localization and enables margin reduction while sparing healthy tissue

Ultra-fast binary MLC enables unprecedented intensity modulation

Excellent target homogeneity while sparing more normal healthy tissue

Source : http://www.accuray.com/media/press-releases/accuray-launches-new-tomotherapy%C2%AE-h%E2%84%A2-series-featuring-tomoedge%E2%84%A2

Full story

Extracellular Matrix Mimetic Library launched by AMSBIO

Extracellular Matrix Mimetic Library launched by AMSBIO

Extracellular Matrix Mimetic Library launched by AMSBIO

AMSBIO is a leading supplier of innovative tools for growing cells in a physiologically relevant manner. A unique Extracellular Matrix (ECM) Mimetic Library for engineering surfaces to direct receptor binding specificity, signalling and growing cells in 3D has been launched.

Containing nearly 300 biomimetics of Fibronectin, Vitronectin, Laminin and Collagen, for coating plates or creating 3D culture scaffolds, AMSBIO’s new ECM combinatorial library provides a powerful tool for identifying the cellular adhesion profile of your cell line or tumour against the widest commercially available collection of cell surface receptor binding peptide motifs.

The extracellular microenvironment, defined by biochemical and physical cues, is a deciding factor in a wide range of cellular processes not confined solely to oncology. These include cell adhesion, proliferation, differentiation, and expression of phenotype-specific functions. Being able to engineer the ECM microenvironment provides clear benefits in studies of cell and tissue engineering and related applications. Currently existing technology offers simple (and merely adequate) environments that facilitate basic cell processes such as adhesion. The simple presentation of motifs involved in cell adhesion is not optimal for controlling more integrated processes. Crosstalk among signalling pathways acts synergistically to enhance cellular responses such as cell adhesion and/or proliferation.

A recent study showed that a combination of extracellular matrix derived peptides presented on a surface may enhance cell adhesion strength and focal adhesion assembly. This combinatorial presentation of ECM peptides on cell growth surfaces may also promote elevated proliferation rates of primary or stem cells.

Based upon the AMSBIO ECM combinatorial library, the ready to-use MAPTrix™ Array provides a means to regulate a variety of cell surface receptors for your cell studies. The basic layout of the MAPTrix™ Array is comprised of avß3 and its complementary integrins such as a2ß1 (collagen), a3ß1 (laminin), a5ß1 (fibronectin), and heparin binding motif.

To learn more preparing a biochemically defined ECM microenvironment and the ECM combinatorial library, please visit www.amsbio.com/downloads/MAPTrix/MAPTrixECMLibrary.pdf or contact AMSBIO on +44-1235-828200 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognised as a leading international provider of unique, innovative products & custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, 3D culture, electrophoresis, glycobiology, post-translational modification & stem cell biology.

Source : http://www.news-medical.net/news/20121030/Extracellular-Matrix-Mimetic-Library-launched-by-AMSBIO.aspx

Full story

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites caused by advanced liver disease. The system is fully implantable, and automatically and continually collects ascites from the abdominal cavity and moves it to the bladder, where it is excreted naturally from the body.

Malignant ascites is an excess build-up of fluid in the abdominal cavity and is a common complication among patients with ovarian, pancreatic and gastric cancer. It is usually managed with large-volume paracentesis, an invasive hospital-based procedure in which the ascites is drained over a number of hours through a large-bore needle inserted in the abdomen.

“CE mark approval of the alfapump® system for patients with malignant ascites is a major milestone for Sequana Medical”, stated Noel L. Johnson, President and CEO of Sequana Medical. “Malignant ascites affects more than 20,000 people per year in the EU. Our system was designed to improve quality of life, so we are very pleased indeed that cancer patients with ascites will now also be able to benefit from our technology.”

Patients no longer experience the discomfort of chronic ascites accumulation and they no longer have to make regular trips to the hospital for paracentesis. By decreasing hospitalization time, the alfapump® system reduces the burden of ascites for patients, physicians and the healthcare system.

“This is an exciting development. The alfapump® system hopes to provide malignant ascites patients with a much-needed new treatment option,” commented Professor Hani Gabra, Professor of Medical Oncology at Imperial College London. “Furthermore, there is enormous potential for this technology in the field of personalized medicine. Ascites can be easily collected via urine sample and then analyzed to determine the presence of certain biomarkers. We are evaluating such urine derived tumour cells and this will allow the physician to quickly identify changes in the disease state and tailor patient treatment accordingly, with a view to improving outcomes”.

Sequana Medical’s PIONEER study, a 40-patient non-randomized trial which concluded in 2011, clearly demonstrated the safety and performance of the alfapump® system and demonstrated a significant reduction in the requirement for paracentesis. Several follow-up studies are currently in the pipeline, including AMAZE, a 50-patient randomized controlled trial in ovarian cancer patients suffering from ascites. This trial be will be led by Professor Gabra of Imperial College London.

Source : http://www.news-medical.net/news/20121030/Sequana-Medical-announces-CE-mark-approval-of-alfapump-for-patients-with-malignant-ascites.aspx

Full story

Varian’s New EDGE Radiotherapy Radiosurgery Suite

Varian’s New EDGE Radiotherapy Radiosurgery Suite

Varian’s New EDGE Radiotherapy Radiosurgery Suite

Varian Medical Systems Unveiled EDGE™ Radiosurgery Suite

A Comprehensive Solution for Non-Invasive Surgical Procedures

EDGE integrates new real-time tumor tracking in end-to-end system for performing radiosurgery anywhere in the body where radiation is indicated

Oct 29, 2012

BOSTON, Oct. 29, 2012 /PRNewswire/ — ASTRO Booth #5019 — Varian Medical Systems (NYSE: VAR) yesterday unveiled its next move against cancer, the new EDGE™ Radiosurgery Suite* — a fully integrated dedicated system for performing advanced radiosurgery using new real-time tumor tracking technology and motion management capabilities.

“Our new EDGE radiosurgery suite represents the first really disruptive technology in radiosurgery in close to two decades, combining state-of-the-art linear accelerator technology with real-time tracking and patient positioning,” said Kolleen Kennedy, president of Varian’s Oncology Systems business. “We designed the EDGE to facilitate fast, accurate delivery of stereotactic radiosurgery to treat any condition amenable to this type of treatment, including tumors of the lung, prostate, brain, spine, and other indications throughout the body.”

As a non-invasive option, radiosurgery utilization has been growing steadily over the last decade for the treatment of cancer and other conditions, and predictions are that it will continue to grow as research accrues about the benefits to patients.[1] Radiosurgery involves the use of sophisticated software and hardware to ablate tumors or other abnormalities with high doses of radiation while minimizing exposure of surrounding healthy tissue.

The EDGE radiosurgery suite combines Varian’s world-class technologies in an end-to-end solution for planning and delivering radiosurgery treatments, encompassing:

Real-time motion management tools, including the Calypso® system and an optical surface monitoring system for real-time tracking of tumor motion during treatment,

Image guidance that encompasses two-, three-, and four-dimensional imaging (the latter showing motion over time) *,

High Intensity Mode for fast dose delivery rates up to an industry-leading 2400 monitor units per minute,

A new PerfectPitch™ treatment couch*, which will give clinicians more options for accessing and treating disease sites by making it possible to adjust the patient’s position along six axes of motion versus four that were in earlier generations of technology,

Varian’s real-time system architecture, which enables an exquisite level of synchronization between imaging, patient positioning, motion management, beam shaping, and dose delivery technologies, performing accuracy checks every ten milliseconds,

Multiple beam shaping options, including Varian’s high-definition multileaf collimator and radiosurgery conical collimators,

Support for both frame-based and frameless approaches to patient immobilization,

Eclipse™ treatment planning software, plus automated contouring tools and an anatomical atlas of templates for expediting the radiosurgery treatment planning process.

Clinicians at the Champalimaud Foundation in Lisbon, Portugal, were among the clinical experts assessing the Edge radiosurgery suite during its development phase. “We have been researching the viability of using single-fraction and hypofractionated radiosurgery to treat primary and oligo-metastatic lesions using earlier TrueBeam™ technology,” says Dr. Carlo Greco, Professor of Radiation Oncology. “It is clear to us that the Edge platform, with its integrated tumor tracking features, will greatly facilitate these advanced, targeted treatments. It overcomes many of the limitations of other technologies, and will make it possible for image-guided radiosurgery to be more widely available to patients who can benefit.”

“Varian’s EDGE will offer clinicians a wide spectrum of capabilities in one smooth end-to-end workflow,” Kennedy said. “With sub-millimeter accuracy, accelerated treatment speeds, and real-time tracking, we feel the EDGE is going to be the sharpest radiosurgery blade on the market.”

Some of the technologies developed for the new EDGE system will also be made available as upgrades to Varian’s current TrueBeam™, Trilogy®, and Clinac® iX treatment platforms.

*The EDGE radiosurgery suite is currently pending FDA 510(k) clearance and not available for sale.

Note to editors: high resolution images of the EDGE radiosurgery suite are available at this URL: http://varian.mediaroom.com/image-gallery?mode=gallery&cat=2874.

[1] Pan H. et al. A survey of stereotactic body radiotherapy use in the United States. Cancer. Volume 117, Issue 19 (October 1, 2011): 4566-4572

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

Varian has unveiled the EDGE, a new radiosurgery system with sub-millimeter accuracy and real-time tumor tracking, at this week’s Annual Meeting of the American Society for Radiation Oncology (ASTRO). It includes capabilities such as high dose radiation delivery of up to 2400 monitor units per minute, a new bed that adjusts on six axes, and continuous correction of beam targeting every ten milliseconds.

The system is currently pending FDA review and is not yet available in the U.S.

Varian EDGE side Varians New EDGE Radiotherapy Radiosurgery SuiteEDGE features from the announcement:

Real-time motion management tools, including the Calypso® system and an optical surface monitoring system for real-time tracking of tumor motion during treatment,

Image guidance that encompasses two-, three-, and four-dimensional imaging (the latter showing motion over time) *,

High Intensity Mode for fast dose delivery rates up to an industry-leading 2400 monitor units per minute,

A new PerfectPitch™ treatment couch*, which will give clinicians more options for accessing and treating disease sites by making it possible to adjust the patient’s position along six axes of motion versus four that were in earlier generations of technology,

Varian’s real-time system architecture, which enables an exquisite level of synchronization between imaging, patient positioning, motion management, beam shaping, and dose delivery technologies, performing accuracy checks every ten milliseconds,

Multiple beam shaping options, including Varian’s high-definition multileaf collimator and radiosurgery conical collimators,

Support for both frame-based and frameless approaches to patient immobilization,

Eclipse™ treatment planning software, plus automated contouring tools and an anatomical atlas of templates for expediting the radiosurgery treatment planning process.

Source : http://varian.mediaroom.com/2012-10-29-Varian-Medical-Systems-Unveiled-EDGE-Radiosurgery-Suite

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 41234
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes